On April 19, the Chinese Academy of Medical Sciences uploaded an article entitled "Rapid development of an inactivated vaccine for SARS-CoV-2" in BioRxiv, which mainly disclosed the animal test data of the COVID-19 inactivated vaccine PiCoVacc , according to the results disclosed in the article, this vaccine has good effect and excellent safety performance.

Now, the researchers follow 5 routes in the development of COVID-19 vaccines, namely traditional attenuated and inactivated vaccines and recombinant vector vaccines, nucleic acid vaccines, and recombinant subunit vaccines based on genetic engineering technology. Compared with other types of vaccines, current virus-inactivated vaccines have advanced research and development technology, mature production technology, and controllable quality standards.

Three vaccines have entered clinical stage in China, including one adenovirus vaccine and two inactivated virus vaccines.

On March 18, the recombinant new coronavirus vaccine (adenovirus vector) ("Ad5-nCoV") developed by Kang Xinuo and the Academy of Military Medical Sciences was approved for clinical use. This is the first new crown vaccine to enter clinical trials in China.

On April 12, the new coronavirus inactivated vaccine declared by the Wuhan Institute of Biological Products and the Wuhan Institute of Virology of the Chinese Academy of Sciences was approved by the State Drug Administration for clinical trials, and Phase I / II clinical trials will be combined. This is the world's first inactivated new coronavirus vaccine that has received clinical trial approval.

Another inactivated virus vaccine under investigation by Beijing Kexing Zhongwei was approved for clinical use on April 13, and the COVID-19 inactivated vaccine for clinical trials has passed the inspection of the Chinese Procuratorate, and the clinical trials have been initiated. The recent research vaccine data published by the Chinese Academy of Medical Sciences in BioRxiv is Kexing's research vaccine, and it is expected that this vaccine will be used in human clinical manifestations.

-----------------------------------------------------------------------
Editor's Note:

PharmaSources.com is a vertical B2B online trade platform serving the pharmaceutical industry,

for any copyright disputes involved in the articles,

please email: Julia.Zhang@imsinoexpo.com to motify or remove the content.